Meningiomas are among the most common primary central nervous system tumours in adults. Studies focused on the molecular basis for meningioma development are hampered by a lack of information with regard to the cell of origin for these brain tumours. Herein, we identify a prostaglandin D synthase-positive meningeal precursor as the cell of origin for murine meningioma, and show that neurofibromatosis type 2 (Nf2) inactivation in prostaglandin D2 synthase (PGDS) ( þ ) primordial meningeal cells, before the formation of the three meningeal layers, accounts for the heterogeneity of meningioma histological subtypes. Using a unique PGDSCre strain, we define a critical embryonic and early postnatal developmental window in which biallelic Nf2 inactivation in PGDS ( þ ) progenitor cells results in meningioma formation. Moreover, we identify differentially expressed markers that characterize the two major histological meningioma subtypes both in human and mouse tumours. Collectively, these findings establish the cell of origin for these common brain tumours as well as a susceptible developmental period in which signature genetic mutations culminate in meningioma formation.
Introduction
Meningiomas account for approximately one-third of all primary central nervous system tumours and constitute the most common brain tumour in adults over 35 years of age. These leptomeningeal neoplasms usually affect older adults, particularly women, and are often associated with significant morbidity (Louis et al., 2000) . Histologically, these tumours exhibit a wide range of histological appearances, with meningothelial, fibroblastic and transitional meningiomas comprising the most common World Health Organization subtypes.
Compared with adult gliomas, relatively less is known about the cell of origin of these tumours or the critical genetic changes that drive tumourigenesis. Insights into the genetic aetiology of meningioma have derived from the study of individuals with the inherited cancer predisposition syndrome neurofibromatosis type 2 (NF2), in which 50% of affected individuals develop meningioma (Evans et al., 1992) . The central role of the NF2 gene in regulating leptomeningeal cell proliferation is underscored by the finding of biallelic NF2 gene inactivation in 50-80% of sporadic meningiomas (Ruttledge et al., 1994; Gutmann et al., 1997) . In particular, NF2 loss is most frequently observed in the fibroblastic histological subtype (Hartmann et al., 2006) .
Previously, we showed that biallelic Nf2 gene inactivation in leptomeningeal cells of genetically engineered mice (GEM) is sufficient for meningioma development. Nf2 inactivation in leptomeningeal cells of newborn Nf2 conditional knockout mice (Nf2 flox2/flox2 ) was accomplished by non-selective cellular targeting with intrathecal adenoviral Cre recombinase delivery (Kalamarides et al., 2002) . Many of these mice developed meningiomas, firmly establishing the critical role of the Nf2 gene in meningioma pathogenesis. However, several important questions remained unaddressed. First, it is unclear which cell type(s) during development and differentiation of the arachnoidal cell lineage represents the cellular target for Nf2 gene inactivation. Second, it is not known how Nf2 loss in these leptomeningeal cells results in the development of the distinct meningioma histological subtypes (Kros et al., 2001; Lee et al., 2006) . Third, is there a specific time window during mouse development when Nf2 inactivation results in meningioma formation?
The purpose of this study was to generate a novel GEM strain to define the cell of origin of meningioma and to explain the spectrum of histological subtypes. Herein, we identified the prostaglandin D2 synthase (PGDS) gene as a specific marker of arachnoidal cells of rats, mice and human beings (Urade et al., 1993; Yamashima et al., 1997; Kawashima et al., 2001) . We leveraged this marker to develop a new transgenic Cre strain to target Nf2 inactivation to PGDS-expressing cells and showed that they are the meningioma cell of origin capable of giving rise to both fibroblastic and meningothelial histological subtypes. Moreover, we show that biallelic Nf2 inactivation in PGDS ( þ ) meningeal progenitor cells must occur during a defined developmental window, such that Nf2 inactivation in PGDS ( þ ) meningeal cells after this period does not result in meningioma development. Finally, we used several human microarray data sets to identify transcripts differentially expressed in fibroblastic and meningiothelial meningioma subtypes, and validated a subset of these markers at the protein level in both human and mouse meningioma tumours. Collectively, these findings establish a PGDS ( þ ) meningeal cell as the cell of origin for the two major meningioma histological subtypes, and define a susceptible developmental window during which Nf2 inactivation leads to meningioma formation.
Results
PGDSCre is expressed at E12.5 in the mouse primordial meningeal cells that give rise to the multiple meningeal layers In the adult arachnoid, PGDS is expressed by arachnoid barrier cells (ABCs), whereas its expression is negligible in arachnoid trabeculae and pia mater (Beuckmann et al., 2000) . Similar to previous studies on human meningiomas (Kalamarides et al., 2008) , we found that both human and mouse meningiomas exhibit intense PGDS immunoreactivity (Supplementary Figure S1) , suggesting that PGDS is a marker of normal and neoplastic arachnoidal cells.
To determine whether early Nf2 inactivation, before the separation of the primordial meninges into the three terminally differentiated layers, might result in meningioma formation in vivo, we generated mice in which Cre recombinase was expressed from the endogenous PDGS promoter to reproduce the spatial and developmental pattern of PGDS expression in the leptomeninges. We elected to employ a knockin approach, as PGDS heterozygous knockout mice are viable with no obvious phenotype (Eguchi et al., 1999) . A nuclear-targeted Cre recombinase gene was integrated into the PGDS coding region by replacing exon 1 of the murine Pdgs gene (Supplementary Figures S2 and S3) .
To define precisely the onset and spatial distribution of PGDSCre expression in the various cell populations of the developing meninges, we first analysed embryos and pups for endogenous meningeal PGDS expression. At E12.5, a single layer of mesoderm-derived undifferentiated cranial mesenchymal cells caudal to Rathke's pouch was positive for PGDS expression (Figures 1a-c) .
These are the first recognizable cells of the developing mesoderm-derived meningeal layer (Kamiryo et al., 1990) . At E15.5, the extracellular space became enlarged around the brain, showing a reticular structure that resembled the subarachnoid space (Figures 1e-g ) (McLone and Bondareff, 1975) . At this stage of development, neural crest-derived undifferentiated cranial mesenchyme rostral to the Rathke's pouch (telencephalic meninges) showed no PGDS immunostaining (Figure 1e ). Starting at E18.5, PGDS immunostaining progressed in a caudal to rostral direction along the telencephalic meninges and was complete by postnatal day 5 (PN5) (Figures 1d, h ), when all arachnoidal cells were PGDS ( þ ) irrespective of their embryological origin or location. In contrast, dura mater cells were negative for PGDS expression ( Figure 1h) .
Next, we characterized the pattern of PGDSCre expression and activity using a LacZ reporter strain (ACZL), in which the chicken b-actin promoter and loxP-flanked CAT gene are upstream of the LacZ gene (Akagi et al., 1997) . In the resulting PGDSCre;ACZL mice, meningeal progenitor cells and all their progeny are identified by LacZ expression and positive X-gal staining. We isolated embryos from these crosses and scored the brain and spinal cord after staining the sections with X-gal. Between E15.5 and E17.0, the primitive interface zone between the dura mater (outer zone) and the arachnoid (inner zone) is formed (Angelov and Vasilev, 1989) . At E18.5, blue cells were observed in both outer (dural border cells, DBCs) and inner (ABCs) zones, whereas only the internal layer was positive for PGDS expression (Figures 2a and b) . These findings indicate that both zones derive from PGDS ( þ ) primordial meningeal cells. In PN3 pups, X-gal ( þ ) cells were also found in the arachnoid at the skull base. By PN5, PGDS ( þ ) cells were observed in the meningeal convexity, a structure that originates from the neural crest (Le Lievre and Le Douarin, 1975) (Figure 1h ). In adult mice, arachnoidal cells were both Cre immunopositive and X-gal positive. In addition, some oligodendrocytes and choroid plexus cells were positive for both Cre and LacZ (Figures 2c, e and f) .
To test whether these PGDS ( þ ) meningeal convexity arachnoidal cells derive from the neural crest, we crossed human tissue plasminogen activator promoter (HtPA)Cre mice with ACZL reporter mice. This transgenic line expresses Cre recombinase under the control of the HtPA (Pietri et al., 2003) . Using this Cre line, X-gal ( þ ) cells emanate from all the known derivatives of cranial, vagal and trunk migratory neural crest cells, including craniofacial structures and cranial ganglia, cardiac and endocrine derivatives, melanocytes, peripheral and enteric nervous system. At E15.5, Cremediated recombination, as revealed by LacZ expression, was evident only in the neural crest-derived meninges along the convexity of the telencephalon (Figure 2d ). In PN3 PGDSCre;ACZL mice, X-galpositive cells were observed in both the DBC and ABC. However, only ABCs were PGDS ( þ ) (Figure 2g ), indicating that both layers derive from a common neural crest precursor. We also monitored PGDSCre-induced
Nf2
flox2 recombination by polymerase chain reaction DNA analysis of adult mouse brain, leptomeninges, spinal cord, peripheral nerves, liver, kidney, lung, heart, spleen, ovary and testis. Only the leptomeninges showed robust levels of recombination, confirming the specificity of this promoter for the arachnoid (data not shown). The low levels of recombination in the brain and spinal cord samples is consistent with previous published data (Hoffmann et al., 1996) , and may indicate the presence of contaminating leptomeninges in these tissue samples. Recombination was also detected in testis and ovary, suggesting germline Cre Figure 1 Spatial and temporal PGDS expression pattern. Sagittal sections through E12.5 (a-c) and E15.5 (e-g) embryos, PN1 (d) and PN3 (h) pups were immunostained with anti-PGDS antibodies. PGDS immunoreactivity was limited to the embryonic meningeal layer (white arrowheads) covering the spinal cord, the rhombencephalon (myelencephalon and metencephalon) surrounding pontine flexure (a, e). No positivity was observed in the meninges covering the telencephalon. At higher magnification (b, f), PGDS immunoreactivity was present in the meninges overlying the basioccipital cartilage and the rhombencephalon in the interpeduncular fossa, caudal to the Rathke's pouch. At E12.5, a single layer of PGDS ( þ ) cells (PrM) indicate the earliest stage in the development of the mesodermderived meninges (c). At E15.5, the subarachnoidal space has developed. DM, atc and PM are PGDS (À) in contrast to the PGDS ( þ ) AL (g). At PN1, PGDS immunostaining showed limited positivity in the meningeal convexity, excluding the DM (d). By PN5, positivity was complete through a caudorostral dynamic progression (h). AL, arachnoid layer; atc, arachnoid trabecular cell; boc, basioccipital cartilage; Br, brain; bv, blood vessel; chp, choroid plexus; Di, diencephalon; DM, dura mater; Me, metencephalon; My, myelencephalon; pfl, pontine flexure; Pg, pituitary gland; PM, pia mater; PrM, primordial meninges; Rp, Rathke's pouch; SAS, subarachnoid space; SC, spinal cord; SV, skull vault; Te, telencephalon.
activity. Consequently, we found that all offspring from male or female mice heterozygous for the PGDSCre allele had demonstrable Cre activity irrespective of whether they inherited the transgene paternally or maternally. Therefore, only PGDSCre;Nf2 flox2/À mice could be used for further analysis.
PGDS promoter-directed biallelic Nf2 inactivation leads to the development of different meningioma histological subtypes To determine whether PGDSCre-mediated Nf2 inactivation results in meningioma formation, we intercrossed PGDSCre;Nf2 flox2/ þ mice with Nf2 flox/flox mice to generate PGDSCre;Nf2 flox2/À mice. PGDSCre;Nf2 flox2/À mice were born at the expected Mendelian frequencies and were monitored closely over a period of 15 months. (Table 1) . Meningioma development was restricted to the skull base ventral to the brainstem, a site where PGDS expression was consistently observed during embryonic development. No meningioma or meningeal abnormalities were found in neural crest-derived meninges along the convexity.
Two major histological meningioma subtypes were observed in these mice: meningothelial meningiomas were restricted to the arachnoid layer, whereas fibroblastic meningiomas were exclusively found emanating from the DBC layer of the dura mater. Meningothelial (Figure 4e ). In nascent meningiomas, the tumour cells resembled normal arachnoidal cells with oval nuclei that, on occasion, showed a central clearing. Nascent meningiomas, located at the arachnoid level attached to the inner surface of the dura mater, showed consistent PGDS immunostaining (Figure 4f ). Vimentin, a universal marker of human meningiomas (Schwechheimer et al., 1984) , was also expressed in 100% of the murine tumours (Figures 4b and c) . In some cases, strong PGDS immunostaining was observed within some regions of the tumour (patchy distribution), whereas in other tumours, only few scattered positive or weakly positive cells were present (Figure 4d) .
Fibroblastic meningiomas were found in six of 16 (38%) PGDSCre;Nf2 flox2/À mice analysed (Figures 4g-i ). These tumours were frequently large. Microscopic examination showed lesions composed of spindleshaped cells embedded in a rich collagen matrix. These meningiomas had the particular feature, not described in human meningiomas, of arising and being restricted to the dura mater, leaving the arachnoid layer intact. All analysed fibroblastic meningiomas were negative for PGDS immunostaining (Figure 4i ). Diagnostic ultrastructural features of fibroblastic meningioma, including spindle-shaped cells with long processes, interdigitating cell processes and scattered desmosomes whorling around collagen nodules were found in one representative meningioma analysed by electron microscopy (Figures 4j-l) . Proliferation of cells in the pia mater and hydrocephalus caused by impaired cerebro-spinal fluid flow were observed in 19% and 13% of the mice, respectively.
In four mice (25%), meningothelial and fibroblastic meningiomas were concomitantly present at the medial skull base. Careful inspection of the meningioma subtypes arising in this GEM model revealed that the two different histological subtypes were each spatially restricted to one meningeal layer: meningothelial meningiomas emanated from the arachnoid layer, whereas fibroblastic meningiomas arose from the dura mater.
Other tumours included osteomas (81%), as previously reported in Nf2 hemizygous mice (Giovannini et al., 2000) , and pituitary adenomas (69%), based on microscopic examination and staining properties (Periodic Acid Schiff staining). The pituitary tumours were negative for PGDS immunostaining.
Additional nullizygosity for p16
Ink4a or p53 does not increase the number and malignancy grade of meningiomas in PGDSCre;Nf2 flox2/À mice We have previously shown using our first-generation GEM meningioma model that additional hemizygosity for p53 did not modify meningioma frequency or progression in AdCre;Nf2 flox2/flox2 mice, whereas p16 ink4a homozygosity increased the frequency of meningioma development without changing malignancy grade. (Figure 3 ). This reduced viability was attributable to the early development (mean age 4.5 months) of highly aggressive osteosarcomas, malignant peripheral nerve sheath tumours (MPNST) and choroid plexus carcinoma. Three cases of choroid plexus hypertrophy were also observed. The finding of osteosarcomas and malignant peripheral nerve sheath tumours is in agreement with our previous reports of osteosarcoma formation in P0Cre;Nf2 þ /À mice with loss of heterozygosity for both Nf2 and p53 (Kalamarides et al., 2002; Robanus-Maandag et al., 2004) . These tumour types belong to the typical tumour spectrum of heterozygous p53 mutant mice (Donehower et al., 1992) , and the strong oncogenic synergy between Nf2 and p53 inactivation in mice is well established (McClatchey et al., 1998; Robanus-Maandag et al., 2004) . In contrast, the choroid plexus hypertrophy and carcinoma are likely related to p53 rather than Nf2 loss, as choroid plexus tumours are frequently observed in the context of the Li-Fraumeni (TP53) inherited cancer syndrome (Krutilkova et al., 2005 Late postnatal and adult adenoviral Cre-mediated Nf2 inactivation in arachnoidal cells does not induce meningioma formation To more precisely define the developmental window during which PGDS ( þ ) cells are susceptible to malignant transformation, we injected Cre adenovirus (adCre) into the cerebro-spinal fluid at the convexity or at the skull base of Nf2 flox2/flox2 mice at PN10 (n ¼ 20) or at 6 weeks of age (adult) (n ¼ 20). We found that Nf2 inactivation in arachnoidal cells at either late postnatal or adult ages did not result in meningioma formation (no tumours at 12 months of age). In contrast, early postnatal Nf2 inactivation in arachnoidal cells generated different meningioma histological subtypes in 23% of adCre-injected PN1-2 pups (Kalamarides et al., 2002 ) (w 2 , P ¼ 0.02). These results show that Nf2 loss in embryonic or very early postnatal PGDS ( þ ) arachnoidal cells induces meningioma formation, whereas arachnoidal cells at later times of development are not susceptible to tumour initiation following Nf2 gene inactivation.
Gene expression profiling supports the existence of a common meningioma progenitor cell for both meningothelial and fibroblastic meningioma development To support the hypothesis that early Nf2 loss in a common meningioma progenitor cell leads to the generation of meningiothelial and fibroblastic meningioma, we used existing human microarray data sets for the these two histological subtypes. First, we applied standard clustering methods to generate an initial list of 31 genes with greater than a fourfold change and a false discovery rate of Po0.1 differentially expressed between fibroblastic (n ¼ 4) and meningothelial (n ¼ 11) meningiomas ( Figure 5 and Table 2 ). We then leveraged previous data from Fevre-Montange et al. (2009) on 17 meningiomas (two meningothelial and three fibrous meningiomas) to identify an additional 32 genes with differential expression in the two histological subtypes. Six of the genes in our initial list were contained in the second data set (highlighted genes in Table 2 ). From this set of six differentially expressed genes, we selected two genes for proof-of-concept validation studies: adenomatosis polyposis coli downregulated (APCDD1) was relatively overexpressed, whereas fibulin 1 (FBLN1) was relatively underexpressed in meningothelial meningiomas relative to fibroblastic meningiomas, respectively. Using an independent set of human meningiomas, we found that the differential pattern of APCDD1 and FBLN1 immunostaining distinguished between meningothelial and fibroblastic meningiomas, consistent with the microarray data. Specifically, APPCDD1 staining was exclusively detected in meningothelial meningiomas (Figures 6a and a 0 ), whereas FBLN1 staining was only found in fibroblastic meningiomas ( Figure 6d ). As seen in the human tumours, we observed APCDD1 staining only in PGDSCre;Nf2 flox2/À mouse meningothelial meningiomas (Figures 6e and e 0 ) and FBLN1 staining only in murine fibroblastic meningiomas (Figure 6f ). These results show that, in human, as in mice, histologically distinct meningioma subsets arise from a shared PGDS ( þ ) progenitor cell following Nf2 inactivation, and argue against the existence of separate cells of origin for these different histological subtypes.
Discussion
The arachnoid is one of the three membranous envelopes (meninges), along with the pia mater and dura mater, which surround the brain and spinal cord. The pia mater is the meningeal envelope that firmly Figure 5 Gene expression profiling of human meningothelial and fibroblastic meningiomas. Heat map representation of fibroblastic (red) compared with meningothelial (blue) meningiomas using 31 genes that are differentially expressed in the two histological subgroups (fold change 44 and false discovery rate, Po0.1).
adheres to the surface of the brain. External to the pia mater is the arachnoid, which is comprised of two regions: a loosely organized inner part with arachnoid trabecular cells delimiting the subarachnoid space filled with cerebro-spinal fluid and an outer layer of closely packed cells with numerous cell junctions (desmosomes and tight and gap junctions) and a basement membrane that forms the ABC to restrict the movement of fluids and large molecular weight substances (Haines et al., 1993) . The outermost of the three meninges is the dura mater (or pachymeninx), a dense membrane that envelops and protects the brain. The dura mater is composed of fibroblasts embedded in an extracellular matrix rich in collagen. One unique population of elongated fibroblasts, DBCs, are present where the innermost part of the dura mater becomes contiguous with the arachnoid (Vandenabeele et al., 1996) .
Integrative data from electron microscopy and immunophenotypic studies in normal arachnoid and meningiomas suggest that arachnoidal cap cells are likely to be the precursor cells of meningioma (Couly and Le Douarin, 1987; Tohma et al., 1992) ; however, this cellular origin has never been experimentally evaluated. In addition, the origin of the meningeal layers remains controversial. Using quail-chick chimeras, all layers of the forebrain meninges as well as bone and overlying dermis originate from the cephalic neural crest (Le Lievre and Le Douarin, 1975; Couly and Le Douarin, 1987) , whereas the meninges covering the brainstem and spinal cord arise from a different embryological lineage, likely the mesoderm (Catala, 1998) . Recent studies using transgenic mice with neural crest (Wnt1Cre)-and mesoderm (Mesp1Cre)-specific promoters have shown that the meninges covering the telencephalon are of neural crest origin, whereas the midbrain meninges derive from the cephalic mesoderm (McBratney-Owen et al., 2008; Yoshida et al., 2008) . In this report, we conclusively establish that the inner part of the dura mater (DBC) and the outer part of the arachnoid (ABC) derive from a common PGDS ( þ ) precursor cell. Moreover, we show that this common precursor cell is of mesoderm origin at the skull base (PGDS ( þ ) meningeal cell), and neural crest derived at the cerebral convexity (telencephalic region). In addition, we show that PGDS serves as both an early marker of mesoderm-derived progenitor cells during late embryogenesis as well as a marker of mature ABCs specialized in cerebro-spinal fluid production.
Importantly, our results show that Nf2 inactivation alone in a PGDS-expressing precursor cell is sufficient for the development of the two predominant meningioma subtypes: meningothelial (PGDS ( þ )) and fibroblastic (PGDS (À)) meningiomas. The co-existence of meningothelial and fibroblastic meningiomas restricted Heterogeneity of meningioma histological subtypes M Kalamarides et al to specific and distinct meningeal layers in PGDSCre;Nf2 flox2/À mice allowed us to identify the progenitor cell for each meningioma subtype (DBCs for fibroblastic meningioma and ABCs for meningothelial meningioma). These observations explain why fibroblastic meningiomas show histological features similar to DBCs, whereas meningothelial meningioma cells are reminiscent of normal arachnoid cells (ABCs). We conclude that differences between the two meningioma subtypes relate to their respective normal cell of origin, DBCs versus ABCs, which share a common PGDS ( þ ) precursor cell. To strengthen this conclusion, we employed human meningioma subtype microarray data to discover two differentially expressed genes that distinguish these two major histological subtypes in both human and mouse meningiomas. Furthermore, we used these markers to show that both of these meningioma subtypes develop from a shared PGDS ( þ ) meningeal progenitor cells following Nf2 inactivation in vivo. This finding is consistent with the normal fate of this progenitor cell, which undergoes lineage commitment to form the two different meningeal layers (dura mater and arachnoid layer).
Lastly, our experimental data support the hypothesis that the developmental stage of arachnoid cells may partly determine their susceptibility to tumour-initiating alterations, such as Nf2 loss. In this regard, we found skull base meningiomas in PGDSCre;Nf2 flox2/À and early postnatal adCre;Nf2 flox2/flox2 mice, in which Nf2 loss occurs in embryonic precursor cells present in the foetal or neonatal meninges. In contrast, meningiomas did not form following Nf2 inactivation when it occurred later in postnatal development or in adult mice. Meningiomas were also not found at the convexity of PGDSCre; Nf2 flox2/À mice, in which Cre expression induces Nf2 loss in more differentiated meningeal cells, or in P0Cre; Nf2 flox2/flox2 mice expressing Cre in the neural crest lineage and derivative meningeal layer (Giovannini et al., 2000) ( Figure 7 ). In the mouse, meningioma initiation requires Nf2 loss during a narrow window of prenatal and perinatal development. Remarkably, in NF2 patients, the tumour burden (including meningiomas) is usually defined at a young age, with fewer tumours arising de novo later in adulthood (da Cruz et al., 2000) . Moreover, the typical growth rate of benign meningiomas is slow (Olivero et al., 1995; Nakamura et al., 2003) , and most meningiomas remain asymptomatic throughout life (Vernooij et al., 2007) , such that nearly half of all meningiomas are incidentally discovered at autopsy (Nakasu et al., 1987) . These observations suggest that meningioma initiation from a common PGDS ( þ ) progenitor cell may be an early event, whereas tumour development may take decades more to form by the addition of genetic and/or epigenetic events.
Collectively, we have generated a new GEM model for meningioma, and used this unique strain to address several unresolved issues germane to meningioma pathogenesis. With the identification of a putative cell of origin and a developmental window for tumour initiation, we are now positioned to develop and evaluate targeted therapies for this common human brain tumour.
Materials and methods
Generation and genotyping of PGDSCre mutant mice Germline chimeras (PGDSCre floxGFPHygro/ þ ) were generated by injection of 10 mutant embryonic stem cells into C57BL/6 blastocysts, and crossed with FVB/N mice to produce outbred heterozygous offspring. The genotypes of all offspring were analysed by polymerase chain reaction or Southern blot analysis on tail-tip DNA. To generate PGDSCre mice, PGDSCre floxGFPHygro/ þ mice were crossed with EIIACre deletor transgenic mice (Lakso et al., 1996) . In the deriving double transgenic offspring XbaI-NdeI digested tail DNA, the PGDSCre allele (13.0 kb) was detected by Southern blot with probe A. Mice carrying the PGDSCre allele were subsequently crossed with FVB/N mice to segregate the mutant allele. ;p16 ink4aÀ/À mice. The p53 flox/flox (Marino et al., 2000) and p16 ink4aÀ/À (Krimpenfort et al., 2001 ) mice were kindly provided by A Berns. All mice used for this analysis were predominantly on a FVB/N mixed strain, with Figure 7 Proposed model of meningioma initiation in the mesoderm-and neural crest-derived meningeal lineages. In the mesodermderived meninges of the skull base, PGDS ( þ ) primordial meningeal cells (E12.5) undergo lineage commitment to form both DBCs (PGDS (À)) in the dura mater and ABCs (PGDS ( þ )) at E15.5. In PGDSCre;Nf2 flox2/À mice, Nf2 loss in embryonic PGDS ( þ ) primordial meningeal cells induces the development of fibroblastic meningiomas in the dura mater and meningothelial meningiomas in the arachnoid layer. These subtypes were also observed following early postnatal (oPN5) Nf2 inactivation in early postnatal PGDS ( þ ) and PGDS (À) meningeal cells following adenoviral Cre injection (AdCre;Nf2 flox2/flox2 mice). More differentiated cells including later postnatal (4PN5) and adult meningeal cells do not form meningiomas following Nf2 inactivation. In the neural crest-derived meninges of the telencephalon, a PGDS (À) neural crest-derived meningeal precursor cell gives rise to both DBC (PGDS ( þ )) and ABC (PGDS (À)). PGDS immunopositivity in ABC appears at E18.5 and is completed by PN5. Susceptibility to Nf2 inactivation resulting in meningioma development is restricted to a temporal window between PN1 and PN5 as determined by the absence of meningioma formation in P0Cre;Nf2 flox2/flox2 (Nf2 inactivation in the primordial meninges of neural crest origin), and in PGDSCre;Nf2 flox2/À and AdCre;Nf2 flox2/À mice (Nf2 inactivation in mature neural crest-derived ABCs and DBCs of the convexity).
contemporaneous littermates serving as controls. Genotyping was performed as described previously (Giovannini et al., 2000) . FVB/N mice were purchased from Charles River Laboratories (Wilmington, MA, USA). Pathogens were tested on a quarterly basis, and all serologies tested were negative throughout the study. All animal care and experimentation reported herein were conducted in compliance with the guidelines and with the specific approval of Institutional Animal Care and Use Committee of the French Department of Agriculture.
Statistics
Significant differences in survival and tumour development were identified using w 2 test; Po0.05 was considered significant.
Molecular analysis of tissues
Genomic DNA was extracted from various tissues of 2-monthold PGDSCre;Nf2 flox2/ þ mice and the recombined Nf2 D2 allele detected by polymerase chain reaction as described previously (Giovannini et al., 2000) .
Histopathology and immunohistochemistry
Mice were euthanized by CO 2 inhalation when seriously ill (rarely) or at 15 months, and a detailed necropsy performed. Histopathological analysis and detection of b-galactosidase activity were performed as described previously (Kalamarides et al., 2002) . For embryo analysis, freshly taken en toto embryos were fixed for 2 h in 0.2% glutaraldehyde-2% formaldehyde-PBS, sagittally sectioned and stained with Xgal before embedding in paraffin as described previously (Kalamarides et al., 2002) . PGDS immunohistochemistry was performed on adjacent paraffin sections using affinity-purified rabbit polyclonal antibodies (1:500, sc-14825; Santa Cruz Biotechnologies, Santa Cruz, CA, USA) and standard techniques (Dako, Carpinteria, CA, USA). Cre immunohistochemistry was performed as described previously (Giovannini et al., 2000) .
Electron microscopy Paraffin-embedded tissue was cut into nine pieces, placed in xylene overnight, rehydrated in graded ethanols (100-25%) and then placed in glutaraldehyde. Subsequently, the tissue was post-fixed in osmium tetroxide, stained with uranyl acetate, dehydrated in graded ethanol solutions, infiltrated with propylene oxide/Epon mixtures, flat embedded in pure Epon and polymerized over night at 60 1C. One-micron sections were cut, stained with toluidine blue and examined by light microscopy. The best section containing meningioma was chosen to proceed for electron microscopy study and trimmed accordingly. Thin sections were cut with an LKB8801 ultramicrotome and diamond knife, stained with Sato's lead and examined in a Phillips 301 transmission electron microscope.
Microarray expression data
Meningioma gene expression data (GEO4780) were obtained from the Gene Expression Omnibus, containing 62 gene expression arrays (five Affymetrix U133A and 57 Affymetrix U133-Plus 2.0 microarrays) as published previously (http:// www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc ¼ GSE4780) (FevreMontange et al., 2009; Stuart et al., 2010) . Histological subtypes were available for 11 meningothelial and four fibroblastic World Health Organization grade I meningiomas. These data were imported into the Partek Genomics Suite version 6.5 (Partek Inc., St Louis, MO, USA), and analysis of variance was employed to detect differentially expressed genes in meningothelial versus fibroblastic meningiomas, using a fold change of greater than 4 and a false discovery rate of Po0.01.
Immunohistochemical validation
Immunohistochemical validation was performed in formalinfixed, paraffin-embedded sections using an independent set of 10 meningothelial and 10 fibroblastic World Health Organization grade I human meningiomas and five meningothelial and five fibroblastic PGDSCre;Nf2 flox2/À mouse meningiomas. FBLN1 and APCDD1 immunohistochemistry were performed using affinity-purified rabbit polyclonal antibodies (FBLN1: Atlas Antibodies, HPA001612 (1:200); APCDD1 Atlas Antibodies, HPA014468 (1:100)).
